Breast cancer screening in an era of personalized regimens: A conceptual model and National Cancer Institute initiative for risk‐based and preference‐based approaches at a population level

Breast cancer screening holds a prominent place in public health, health care delivery, policy, and women's health care decisions. Several factors are driving shifts in how population‐based breast cancer screening is approached, including advanced imaging technologies, health system performance measures, health care reform, concern for “overdiagnosis,” and improved understanding of risk. Maximizing benefits while minimizing the harms of screening requires moving from a “1‐size‐fits‐all” guideline paradigm to more personalized strategies. A refined conceptual model for breast cancer screening is needed to align women's risks and preferences with screening regimens. A conceptual model of personalized breast cancer screening is presented herein that emphasizes key domains and transitions throughout the screening process, as well as multilevel perspectives. The key domains of screening awareness, detection, diagnosis, and treatment and survivorship are conceptualized to function at the level of the patient, provider, facility, health care system, and population/policy arena. Personalized breast cancer screening can be assessed across these domains with both process and outcome measures. Identifying, evaluating, and monitoring process measures in screening is a focus of a National Cancer Institute initiative entitled PROSPR (Population‐based Research Optimizing Screening through Personalized Regimens), which will provide generalizable evidence for a risk‐based model of breast cancer screening, The model presented builds on prior breast cancer screening models and may serve to identify new measures to optimize benefits‐to‐harms tradeoffs in population‐based screening, which is a timely goal in the era of health care reform. Cancer 2014;120:2955–2964. © 2014 American Cancer Society.

[1]  A. Chagpar,et al.  Epidemiology of Ductal Carcinoma In Situ , 2015 .

[2]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[3]  P. Gøtzsche,et al.  Screening for breast cancer with mammography. , 2013, The Cochrane database of systematic reviews.

[4]  John Brodersen,et al.  Long-Term Psychosocial Consequences of False-Positive Screening Mammography , 2013, The Annals of Family Medicine.

[5]  A. Bleyer,et al.  Effect of three decades of screening mammography on breast-cancer incidence. , 2012, The New England journal of medicine.

[6]  S. Taplin,et al.  A Multilevel Research Perspective on Cancer Care Delivery: The Example of Follow-Up to An Abnormal Mammogram , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[7]  S. Taplin,et al.  Introduction: Understanding and influencing multilevel factors across the cancer care continuum. , 2012, Journal of the National Cancer Institute. Monographs.

[8]  C. Gross,et al.  Older patient experiences in the mammography decision-making process. , 2012, Archives of internal medicine.

[9]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[10]  Natasha K. Stout,et al.  To Screen or Not to Screen Women in Their 40s for Breast Cancer: Is Personalized Risk-Based Screening the Answer? , 2011, Annals of Internal Medicine.

[11]  B. Graubard,et al.  Data and trends in cancer screening in the United States , 2010, Cancer.

[12]  Joann G Elmore,et al.  Cost of Breast-Related Care in the Year Following False Positive Screening Mammograms , 2010, Medical care.

[13]  Julietta Patnick,et al.  Breast and cervical cancer screening programme implementation in 16 countries , 2010, Journal of medical screening.

[14]  Leonard Berlin,et al.  More mammography muddle: emotions, politics, science, costs, and polarization. , 2010, Radiology.

[15]  S. Taplin,et al.  Factors in quality care--the case of follow-up to abnormal cancer screening tests--problems in the steps and interfaces of care. , 2010, Journal of the National Cancer Institute. Monographs.

[16]  C. D'Orsi,et al.  Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. , 2010, Journal of the American College of Radiology : JACR.

[17]  M. Plescia,et al.  Vital signs: breast cancer screening among women aged 50-74 years - United States, 2008. , 2010, MMWR. Morbidity and mortality weekly report.

[18]  L. Irwig,et al.  Estimates of overdiagnosis of invasive breast cancer associated with screening mammography , 2010, Cancer Causes & Control.

[19]  Karla Kerlikowske,et al.  Evidence-Based Breast Cancer Prevention: The Importance of Individual Risk , 2009, Annals of Internal Medicine.

[20]  Marvin Zelen,et al.  Clinical Guidelines Annals of Internal Medicine Effects of Mammography Screening Under Different Screening , 2022 .

[21]  Laura Esserman,et al.  Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.

[22]  D. Miglioretti,et al.  Association between Breast Density and Subsequent Breast Cancer Following Treatment for Ductal Carcinoma In situ , 2007, Cancer Epidemiology Biomarkers & Prevention.

[23]  S. Fletcher,et al.  The effect of immediate reading of screening mammograms on medical care utilization and costs after false-positive mammograms. , 2007, Health services research.

[24]  C. Klabunde,et al.  Evaluating Population-Based Screening Mammography Programs Internationally. , 2007, Seminars in breast disease.

[25]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[26]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[27]  L. Tabár,et al.  Overdiagnosis and overtreatment of breast cancer: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer , 2005, Breast Cancer Research.

[28]  C. D'Orsi,et al.  Diagnostic Performance of Digital Versus Film Mammography for Breast-Cancer Screening , 2005, The New England journal of medicine.

[29]  S. Devesa,et al.  Probabilities of death from breast cancer and other causes among female breast cancer patients. , 2004, Journal of the National Cancer Institute.

[30]  T. Tuttle,et al.  Trends in the treatment of ductal carcinoma in situ of the breast. , 2004, Journal of the National Cancer Institute.

[31]  Michael Merbaum,et al.  Coping and anxiety in women recalled for additional diagnostic procedures following an abnormal screening mammogram. , 2004, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[32]  B. Weber,et al.  Application of breast cancer risk prediction models in clinical practice. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Manos,et al.  A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  Ingvar Andersson,et al.  Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.

[35]  A. Miller Screening for breast cancer with mammography , 2001, The Lancet.

[36]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[37]  G. Colditz,et al.  Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  V. Ernster,et al.  Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. , 1997, Journal of the National Cancer Institute. Monographs.